Font Size Smaller Font Size
Larger Font Size
Latest Press Releases
-
July 26, 2018
Celgene Reports Second Quarter 2018 Operating and Financial Results
-
July 23, 2018
Celgene Announces Phase III ‘AUGMENT' Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint
-
July 10, 2018
Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
-
July 9, 2018
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia
-
July 2, 2018
Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018
No results found.